-
Featured
Ultrasound Therapy Yields Promising Results for Localized Prostate Cancer
At the American Urological Association's 2019 Annual Meeting, researchers presented the findings of a study on the effects transurethral ultrasound ablation (TULSA), a novel minimally invasive procedure that can reduce prostate size and prostate-specific antigens in patients with localized prostate cancer.
-
Featured
Improving the Safety of Vena Caval Thrombectomy in Kidney Cancer with Tumor Thrombus Team Approach
Complete removal of a tumor thrombus resulting from venous tumor invasion is essential for eliminating the cancer in patients with advanced renal cell carcinoma (RCC). A multispecialty tumor thrombus team within an integrated practice can improve the safety of this intricate and extensive procedure.
-
Featured
Laterality of Renal Cell Carcinoma Predicts Survival in Certain Patient Subgroups
Patients with right-sided renal cell carcinoma are significantly more likely to have favorable clinicopathological features than patients with left-sided disease, and they have significantly better cancer-specific survival within certain subgroups.
-
Genetic Signature Predicts Metastasis, Survival in Clear Cell Renal Cell Carcinoma
Shenglin Mei, PhD, Philip J. Saylor, MD, David B. Sykes, MD, PhD, and colleagues found that simultaneous expression of four specific genes predicts survival and metastasis in human clear cell renal cell carcinoma, and they identified other potential therapeutic targets.
-
Transperineal Prostate Biopsy Feasible in Outpatient Practice
Douglas M. Dahl, MD, and colleagues reviewed their initial experience with in-office transperineal prostate biopsy. After 130 procedures, they noted no infectious complications and an antibiotic utilization rate of 48%.
-
Using Machine Learning to Predict Prostate Cancer Progression During Active Surveillance
Madhur Nayan, MDCM, PhD, and Adam S. Feldman, MD, MPH, and colleagues created the first machine learning models for predicting prostate cancer progression during active surveillance and found they outperformed traditional logistic regression.
Mass General Cancer Center Contributors
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Case Series: Mucinous Adenocarcinoma of the Prostatic Urethra After Brachytherapy for Prostatic Adenocarcinoma
-
David T. Miyamoto, MD, PhD
Attending Radiation Oncologist, Department of Radiation Oncology, Massachusetts General Hospital, Investigator, Center for Cancer Research, Mass General Cancer Center, Assistant Professor of Radiation Oncology, Harvard Medical School
Recent Article
High MRE11 in Muscle-invasive Bladder Tumors Linked to Better Survival After Chemoradiation -
Douglas Middleton Dahl, MD
Chief, Division of Urologic Oncology, Director of Robotic Surgery, Massachusetts General Hospital, Associate Professor of Surgery (Urology), Harvard Medical School
Recent Article
Genetic Signature Predicts Metastasis, Survival in Clear Cell Renal Cell Carcinoma
-
-
Jason A. Efstathiou, MD, DPhil
Vice-Chair, Faculty & Academic Affairs, Director, Genitourinary Service, Department of Radiation Oncology, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic, Massachusetts General Hospital
Recent Article
High MRE11 in Muscle-invasive Bladder Tumors Linked to Better Survival After Chemoradiation
Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program
Physicians in the Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program specialize in using advanced surgical therapies and minimally invasive procedures to treat male and female genitourinary cancers.
